Journal of Chest Surgery最新文献

Double Lung Transplantation Using Bilateral Anterior Thoracotomies with Video-Assistance: Techniques, Advantages, and Considerations. 视频辅助双侧前开胸双肺移植：技术、优势和注意事项。

Journal of Chest Surgery Pub Date : 2025-07-05 Epub Date: 2025-03-04 DOI: 10.5090/jcs.24.115

Samina Park

引用次数: 0

The Impact of Sarcopenia on Early Postoperative Complications in Patients Undergoing Decortication due to Empyema: A Retrospective Study in Turkey. 土耳其一项回顾性研究：因肺水肿接受去骨瓣术的患者中，肌肉疏松症对术后早期并发症的影响：土耳其的一项回顾性研究

Journal of Chest Surgery Pub Date : 2025-07-05 Epub Date: 2025-03-14 DOI: 10.5090/jcs.24.086

Tolga Semerkant, Arif Ates, Tuğçe Semerkant, Ferdane Melike Duran, Mustafa Gültekin, Hıdır Esme

{"title":"The Impact of Sarcopenia on Early Postoperative Complications in Patients Undergoing Decortication due to Empyema: A Retrospective Study in Turkey.","authors":"Tolga Semerkant, Arif Ates, Tuğçe Semerkant, Ferdane Melike Duran, Mustafa Gültekin, Hıdır Esme","doi":"10.5090/jcs.24.086","DOIUrl":"10.5090/jcs.24.086","url":null,"abstract":"Background: Sarcopenia is a progressive skeletal muscle disorder characterized by the loss of muscle mass and function. Computed tomography (CT) scans are a reliable method for diagnosing sarcopenia, as they allow for the measurement of muscle density using Hounsfield units (HU). In this study, we conducted a retrospective investigation into the prevalence of sarcopenia and its impact on postoperative complications in patients who underwent decortication for empyema.Methods: Between September 2020 and August 2023, we measured the average HU values of the bilateral paravertebral muscles at the T12 thoracic vertebra level using CT. This study included 145 patients who underwent thoracotomy and decortication for empyema at the Thoracic Surgery Clinic of Konya City Hospital. Based on their HU values, patients were categorized into 2 groups: the sarcopenia group (group S) and the control group (group C). Our objectives were to determine the prevalence of sarcopenia in these patients, evaluate its influence on early postoperative complications, and explore its potential role as a risk factor for postoperative complications.Results: Sarcopenia was identified in 49 (33.7%) of the patients who underwent thoracotomy and decortication for empyema. In group S, the rates of postoperative surgical site infection and pneumonia were significantly higher. Regression analysis revealed that sarcopenia was an independent risk factor for both postoperative pneumonia and surgical site infection. Additionally, the length of stay in the intensive care unit and the hospital was significantly longer in group S than in group C.Conclusion: In patients who underwent thoracotomy for empyema, sarcopenia independently increases the risk of postoperative pneumonia and surgical site infections.","PeriodicalId":34499,"journal":{"name":"Journal of Chest Surgery","volume":" ","pages":"148-156"},"PeriodicalIF":0.0,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary: Real-World Insights into Adjuvant Immunotherapy after Esophagectomy. 评论：食道切除术后辅助免疫治疗的真实世界见解。

Journal of Chest Surgery Pub Date : 2025-07-05 DOI: 10.5090/jcs.25.065

Min Hee Hong

引用次数: 0

Commentary: Advancing toward Minimally Invasive Lung Transplantation. 评论：微创肺移植的进展。

Journal of Chest Surgery Pub Date : 2025-07-05 Epub Date: 2025-04-22 DOI: 10.5090/jcs.25.032

Jin Gu Lee

引用次数: 0

The Past, Present, and Future of Off-Pump Coronary Artery Bypass Grafting. 非体外循环冠状动脉旁路移植术的过去、现在和未来。

Journal of Chest Surgery Pub Date : 2025-07-05 Epub Date: 2025-04-15 DOI: 10.5090/jcs.24.122

Kyung-Jong Yoo

{"title":"The Past, Present, and Future of Off-Pump Coronary Artery Bypass Grafting.","authors":"Kyung-Jong Yoo","doi":"10.5090/jcs.24.122","DOIUrl":"10.5090/jcs.24.122","url":null,"abstract":"The evolution of treatment for ischemic heart disease has been driven by advancements in both diagnostic and therapeutic methods, including coronary angiography, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). Initially, CABG relied on on-pump techniques using saphenous vein grafts; however, off-pump coronary artery bypass grafting (OPCAB) emerged as an alternative to reduce complications associated with cardiopulmonary bypass. Despite potential benefits-such as a reduced risk of stroke, shorter hospital stays, and fewer respiratory and renal complications-OPCAB has seen limited adoption, particularly in Western countries, owing to its technical demands and concerns regarding graft patency and complete revascularization. Large-scale randomized trials have reported mixed results, with outcomes strongly influenced by surgeon experience and patient selection. In contrast, smaller studies by experienced surgeons have demonstrated comparable graft patency and superior outcomes in high-risk patients. Recent meta-analyses underscore the need for total arterial revascularization and no-touch aortic techniques to further optimize OPCAB results, particularly in high-risk populations. Moving forward, OPCAB shows significant promise for patients with severe comorbidities, such as those with calcified aortas or poor ventricular function. Enhanced training programs and hybrid revascularization strategies that integrate minimally invasive CABG with PCI could further expand OPCAB adoption. By leveraging its unique strengths-including reduced postoperative complications and improved outcomes for high-risk patients-OPCAB could play a pivotal role in modern cardiac surgery. To remain competitive with PCI, surgeons must actively prepare for OPCAB by developing expertise in both techniques tailored to the patient's clinical condition.","PeriodicalId":34499,"journal":{"name":"Journal of Chest Surgery","volume":" ","pages":"121-133"},"PeriodicalIF":0.0,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Missing Guidewire in a Bulla: A Case Report. 子弹丢失导丝一例报告。

Journal of Chest Surgery Pub Date : 2025-07-05 Epub Date: 2025-06-04 DOI: 10.5090/jcs.25.023

Hee Chul Yang, Sarah Nisivaco, Chitaru Kurihara

引用次数: 0

Journal of Chest Surgery Achieves Impact Factor 1.0: Laying the Foundation for Global Growth. 《胸外科杂志》达到影响因子1.0：为全球增长奠定基础。

Journal of Chest Surgery Pub Date : 2025-07-05 DOI: 10.5090/jcs.25.070

Seong Yong Park

引用次数: 0

Preliminary Real-World Outcomes of Adjuvant Immunotherapy in Resected Esophageal Cancer: A Retrospective Study from Taiwan. 食管癌切除后辅助免疫治疗的初步实际预后：台湾回顾性研究。

Journal of Chest Surgery Pub Date : 2025-07-05 DOI: 10.5090/jcs.25.024

Chia Liu, Yi-Chen Yeh, Ling-I Chien, Chien-Sheng Huang, Han-Shui Hsu, Po-Kuei Hsu

{"title":"Preliminary Real-World Outcomes of Adjuvant Immunotherapy in Resected Esophageal Cancer: A Retrospective Study from Taiwan.","authors":"Chia Liu, Yi-Chen Yeh, Ling-I Chien, Chien-Sheng Huang, Han-Shui Hsu, Po-Kuei Hsu","doi":"10.5090/jcs.25.024","DOIUrl":"10.5090/jcs.25.024","url":null,"abstract":"Background: The CheckMate 577 trial demonstrated that adjuvant nivolumab improves disease-free survival in patients with resected esophageal cancer following neoadjuvant chemoradiotherapy. This study aimed to evaluate real-world outcomes associated with adjuvant immunotherapy.Methods: Patients with esophageal cancer and residual pathological disease who underwent neoadjuvant therapy followed by surgical resection between January 2019 and February 2024 were retrospectively analyzed. Participants were grouped by adjuvant treatment received: no adjuvant therapy, adjuvant immunotherapy (AI), or adjuvant chemotherapy (AC). Primary outcomes included overall survival (OS) and recurrence-free survival (RFS). Subgroup analyses were performed for patients meeting CheckMate 577 eligibility criteria and those with pathological node-positive (ypN+) status.Results: The study included 127 patients (mean age: 60 years; male: 86%): 23 received AI, 36 AC, and 68 received no adjuvant therapy. There were no significant differences in OS between AI and AC groups (median OS [mOS]: 34 months vs. 34 months; p=0.81), nor in RFS (median RFS [mRFS]: 15 months vs. 16 months; p=0.94). In the CheckMate 577-eligible subgroup (n=68), OS and RFS were similar between AI and AC groups (mOS: 25 months vs. 47 months; p=0.16; mRFS: 19 months vs. 20 months; p=0.74). Likewise, among ypN+ patients (n=54), no significant differences in OS or RFS were noted between AI and AC (mOS: 34 months vs. 31 months; p=0.74; mRFS: 9.5 months vs. 14 months; p=0.89).Conclusion: AI did not demonstrate a significant survival advantage compared to AC, even in patients meeting CheckMate 577 criteria or those with ypN+ status. Identifying the optimal adjuvant treatment for esophageal cancer remains a challenging and evolving issue.","PeriodicalId":34499,"journal":{"name":"Journal of Chest Surgery","volume":"58 4","pages":"134-145"},"PeriodicalIF":0.0,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why Open Surgical Repair Remains Essential: Insights into the Suitability of Endovascular Aneurysm Repair in Ruptured Abdominal Aortic Aneurysms from a Tertiary Referral Center in South Korea. 为什么开放手术修复仍然是必要的：韩国三级转诊中心对破裂腹主动脉瘤血管内修复的适用性的见解。

Journal of Chest Surgery Pub Date : 2025-06-04 DOI: 10.5090/jcs.24.116

Sang Yoon Kim, Dong Kyu Yoon, Jae Hang Lee, Hyoung Woo Chang, Kay-Hyun Park

{"title":"Why Open Surgical Repair Remains Essential: Insights into the Suitability of Endovascular Aneurysm Repair in Ruptured Abdominal Aortic Aneurysms from a Tertiary Referral Center in South Korea.","authors":"Sang Yoon Kim, Dong Kyu Yoon, Jae Hang Lee, Hyoung Woo Chang, Kay-Hyun Park","doi":"10.5090/jcs.24.116","DOIUrl":"https://doi.org/10.5090/jcs.24.116","url":null,"abstract":"Background: Several studies have demonstrated that emergency endovascular aneurysm repair (eEVAR) has become the standard treatment for ruptured abdominal aortic aneurysm (rAAA) compared to open surgical repair (OSR). This study investigated the feasibility of eEVAR in rAAA patients and analyzed the outcomes of OSR.Methods: At our institution, all patients (n=58) presenting with rAAA underwent OSR. We conducted a retrospective review of surgically treated rAAA patients between February 2006 and March 2021. Patients with impending rupture or isolated iliac aneurysm rupture were excluded.Results: Anatomic measurements based on preoperative computed tomography indicated that 28 patients (48.3%) could have been candidates for eEVAR. Reasons for unsuitability included: (1) proximal neck length <10 mm (n=21, 51.7%); (2) proximal neck angulation >60° (n=11, 19.0%); (3) iliac artery diameter <5 mm (n=6, 10.3%); and (4) proximal neck diameter >32 mm (n=3, 5.2%). The 30-day mortality rate for OSR was 17.2% (n=10). The 1-year and 5-year survival rates were 53.4%±6.5% and 33.4%±6.3%, respectively. Multivariable logistic regression analysis revealed that a high preoperative serum lactate level (>5 mmol/L) and the presence of bowel ischemia were significant risk factors for 30-day mortality (odds ratio [OR], 11.95; 95% confidence interval [CI], 1.53-93.08; p<0.018; and OR, 15.28; 95% CI, 1.60-146.18; p<0.018, respectively).Conclusion: More than half of rAAA patients were not candidates for eEVAR due to various anatomical reasons. OSR demonstrated favorable short- and long-term outcomes and remains a viable standard treatment for rAAA.","PeriodicalId":34499,"journal":{"name":"Journal of Chest Surgery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asia-Pacific Innovative Thoracic Surgery Symposium 2025. 亚太创新胸外科研讨会2025。

Journal of Chest Surgery Pub Date : 2025-05-29 DOI: 10.5090/jcs.2025.58.Suppl-1

引用次数: 0